Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Current Assets (2016 - 2025)

VYNE Therapeutics' Current Assets history spans 10 years, with the latest figure at $30.0 million for Q4 2025.

  • For Q4 2025, Current Assets fell 53.43% year-over-year to $30.0 million; the TTM value through Dec 2025 reached $30.0 million, down 53.43%, while the annual FY2025 figure was $30.0 million, 53.43% down from the prior year.
  • Current Assets reached $30.0 million in Q4 2025 per VYNE's latest filing, down from $44.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $143.1 million in Q1 2021 to a low of $17.5 million in Q3 2023.
  • Average Current Assets over 5 years is $64.0 million, with a median of $60.7 million recorded in 2022.
  • Peak YoY movement for Current Assets: tumbled 60.24% in 2023, then skyrocketed 319.94% in 2024.
  • A 5-year view of Current Assets shows it stood at $63.2 million in 2021, then tumbled by 39.42% to $38.3 million in 2022, then skyrocketed by 150.72% to $96.0 million in 2023, then crashed by 32.85% to $64.4 million in 2024, then plummeted by 53.43% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Current Assets are $30.0 million (Q4 2025), $44.3 million (Q2 2025), and $54.9 million (Q1 2025).